High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cardiotoxicity
/ etiology
Cyclophosphamide
/ therapeutic use
Doxorubicin
/ adverse effects
Female
Follow-Up Studies
Humans
Lymphoma, B-Cell
/ drug therapy
Lymphoma, Large B-Cell, Diffuse
/ drug therapy
Male
Methotrexate
/ therapeutic use
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Positron Emission Tomography Computed Tomography
Rituximab
/ therapeutic use
Vincristine
/ therapeutic use
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 06 2022
22 06 2022
Historique:
received:
08
12
2021
accepted:
31
05
2022
entrez:
22
6
2022
pubmed:
23
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Primary mediastinal B-cell lymphoma (PMBL) is currently curable in 85-95% of patients. Treatment regimens frequently used include RCHOP ± radiotherapy, DAEPOCH-R, or occasionally more intensive protocols. Here we present results of treatment of 124 patients with PMBL over a period between 2004 and 2017 with the use of a protocol designed for aggressive B-cell lymphoma GMALL/B-ALL/NHL2002 including 6 cycles of alternating immunochemotherapy with intermediate-dose methotrexate in each cycle, and reduced total doxorubicin dose (100 mg/m
Identifiants
pubmed: 35732790
doi: 10.1038/s41598-022-14067-3
pii: 10.1038/s41598-022-14067-3
pmc: PMC9217998
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10551Informations de copyright
© 2022. The Author(s).
Références
BMC Cancer. 2017 May 22;17(1):359
pubmed: 28532396
J Clin Oncol. 2019 Nov 20;37(33):3081-3089
pubmed: 31398081
Am J Hematol. 2011 Dec;86(12):E61-4
pubmed: 21898532
N Engl J Med. 2013 Apr 11;368(15):1408-16
pubmed: 23574119
Br J Haematol. 2018 Feb;180(4):534-544
pubmed: 29265182
Blood Cancer J. 2015 Dec 04;5:e372
pubmed: 26636287
Cancers (Basel). 2021 Apr 15;13(8):
pubmed: 33921074
Eur J Haematol. 2020 Jan;104(1):59-66
pubmed: 31606909
Ann Oncol. 2011 Mar;22(3):664-670
pubmed: 20724576
Cancer Med. 2015 Jan;4(1):7-15
pubmed: 25205600
Leuk Lymphoma. 2014 Mar;55(3):538-43
pubmed: 23734654
Haematologica. 2018 Aug;103(8):1337-1344
pubmed: 29748435
Oncologist. 2021 Jul;26(7):597-609
pubmed: 33870594
Pol J Pathol. 2002;53(3):139-44
pubmed: 12476616
J Clin Oncol. 2021 Nov 20;39(33):3716-3724
pubmed: 34570655
Ann Hematol. 2009 May;88(5):433-9
pubmed: 18853160
Br J Cancer. 2004 Jan 26;90(2):372-6
pubmed: 14735179
Br J Haematol. 2016 Nov;175(4):668-672
pubmed: 27477167
Blood. 2018 Nov 29;132(22):2401-2405
pubmed: 30257882
BMC Cancer. 2017 Apr 17;17(1):276
pubmed: 28415982
Leukemia. 2016 Jan;30(1):238-42
pubmed: 25971363
J Clin Oncol. 1999 Apr;17(4):1244
pubmed: 10561185
Hematol Oncol. 2015 Dec;33(4):145-50
pubmed: 25256959
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Cancer Chemother Pharmacol. 2016 May;77(5):1053-60
pubmed: 27056383
J Clin Oncol. 2019 Dec 1;37(34):3291-3299
pubmed: 31609651
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Blood. 2003 Dec 1;102(12):3871-9
pubmed: 12933571
Br J Haematol. 2017 Dec;179(5):739-747
pubmed: 29082519
Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):126-132
pubmed: 26547384
Ann Hematol. 2021 Jun;100(6):1517-1524
pubmed: 33216199
Ann Oncol. 2007 Jan;18(1):149-157
pubmed: 17018708
Br J Haematol. 2018 Dec;183(5):717-726
pubmed: 30406945
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Blood. 2014 Dec 18;124(26):3870-9
pubmed: 25359988
Oncologist. 2012;17(2):239-49
pubmed: 22282906
Blood. 2020 Dec 10;136(24):2803-2811
pubmed: 32603413
Leuk Lymphoma. 2008 Jul;49(7):1329-36
pubmed: 18604722
Haematologica. 2014 Dec;99(12):1817-25
pubmed: 25216682